GILD

Finding Value In The S&P 500: 9 Healthcare Dividend Growth Stocks: Part 1

2016-08-04

Research Articles

Introduction Most everyone would agree that the stock market as measured by the S&P 500 is not cheap today.  However, there might be a great deal of disagreement regarding precisely how overvalued the S&P 500 currently is.  Nevertheless, I would agree that in the general sense, stocks are not exactly bargains today.  This might especially […]

12 Attractive Fast-Growing Dividend Growth Stocks for High Total Return

2015-08-27

Research Articles

Introduction The current market environment is presenting many challenges to the conservative retired investor in need of current income.  Interest rates are near all-time lows and the valuations of many blue-chip dividend growth stocks have become extended.  Consequently, it is becoming very difficult to find quality investment opportunities that can provide safety through sound valuation, […]

Why Gilead Is The Most Exciting Growth Opportunity In 2014

2014-08-15

Research Articles

Introduction Earnings drive stock price in the long run and Gilead Sciences Inc (GILD) is entering a remarkable period of what could only be called astounding future earnings growth.  This has not gone unnoticed by the market, as the stock price has been on a steady ascent for the past several months. Furthermore, there have […]

Stocks 2014: Investing for Growth – The Power and Protection of High Compounding Earnings Growth – Part 2

2013-01-16

Research Articles

As I become more mature (translate: gotten older), my investment philosophy has slowly evolved into a more conservative posture.  When I was a younger investor I felt I had time on my side, and therefore, was willing to take on greater risk as long as I believed that greater rewards could follow.  In other words, […]

Gilead Sciences Inc: Strong Growth At An Unreasonably Low Price

2012-05-21

FAST Graphs At-A-Glance

Gilead Sciences Inc (GILD) is an innovative healthcare company with a strong record of historical earnings growth and expectations for above-average growth into the future.  Nevertheless, Mr. Market seems unwilling to recognize the past and future earnings power of this niche pharmaceutical growth stock.  Consequently, the company trades at a single digit PE ratio that […]

Disclaimers: F.A.S.T. Graphs, Inc. is not a broker-dealer or a registered investment adviser. Under no circumstances does any information on Fastgraphs.com constitute a recommendation to buy or sell a security, nor does it give investment advice. This is to include any publications or articles on Fastgraphs.com. Fastgraphs.com is a research tool to be used by its subscribers in conjunction with the subscribers’ additional research and due diligence. The information on this site is in no way guaranteed for completeness or accuracy.